Compare Lowe`s Companies Inc (LOW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Recursion Pharmaceuticals Inc — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Lowe`s Companies Inc is far larger — about 49.5× Recursion Pharmaceuticals Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LOW | RXRX | |
|---|---|---|
Market Cap | $105.96B | $2.14B |
Volume | 4,039,547 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $6.79 |
52-Week Low | $179.50 | $2.84 |
Typical Hold Time | 98 Days | 23 Days |
Enterprise Value | $144.81B | $1.66B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with recent earnings beats but faces a bearish technical outlook. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue declined to $83.67B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector contends with a slowing housing market.
Wall Street maintains a bullish consensus with a $244.09 price target (60.8% buy ratings), but risks include high debt levels and economic sensitivity. The stock offers value with dividend payments, yet investors must weigh competitive pressures and macroeconomic headwinds against its innovation efforts and market position.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
